Retatrutide is a cutting-edge investigational peptide that acts as a triple agonist of the GIP, GLP-1, and Glucagon receptors. It represents the most advanced incretin-based compound currently in research for weight management and metabolic health.
Full compound guide: https://www.auspeps.com/blogs/guides/retatrutide-2026-guide-triple-agonist-peptide-mechanisms-clinical-results-dosing-research-insights
Key Features
- Simultaneous activation of GIP + GLP-1 + Glucagon receptors
- Superior weight loss potential compared to dual agonists
- Once-weekly subcutaneous injection
- Long half-life (~6 days)
- Enhances energy expenditure while suppressing appetite
Research Highlights
Weight Loss
Up to 24.2% body weight reduction in 48 weeks (Phase 2, 12mg dose).
Metabolic Health
Significant improvements in HbA1c, fasting glucose, waist circumference, liver fat, and blood pressure.
Mechanism
Combines appetite control (GLP-1/GIP) with increased energy expenditure (Glucagon).
Typical Research Dosing Protocol
| Week | Dose |
|---|---|
| Weeks 1–4 | 1 – 4 mg weekly |
| Weeks 5–8 | 4 – 8 mg weekly |
| Maintenance | 8 – 12 mg weekly |
Product Specifications
- Form: Lyophilized powder in vial
- Purity: ≥99% (HPLC verified)
- Reconstitution: Use bacteriostatic water
- Storage: Refrigerate after reconstitution
For Research Use Only. Not for human consumption. Retatrutide is intended strictly for laboratory and scientific research purposes.
